Numerate in collaboration with Robert Mahley, MD, PhD, at Gladstone Institute at UCSF, have received a Seeding Drug Discovery Award from the Wellcome Trust to pursue novel Alzheimer’s therapeutics. Together we will use the funding to identify new chemical compounds that can target apolipoprotein E4 (apoE4) — the strongest genetic risk factor for developing Alzheimer’s.
